Short description
Glaukos is a glaucoma treatment company developing micro-bypass therapies to moderate the intraocular pressures that help preserve vision.
Description
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm.
They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.
In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
San Clemente, California, United States, North America
Founded on
January 1, 1998
Exited on
June 25, 2015
Went public on
June 25, 2015
Stock symbol
GKOS
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Blurry Noaccess, Absolutely Noaccess, No Way, Noaccess, Noway Youcantaccess, Absolutely Noaccess, Cannot Access
Sign in for full access
Founders
Mory Gharib, Olav Bergheim, Richard A. Hill